Norihisa Hanada
About
In The Last Decade
Norihisa Hanada
21 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Molecular Biology 853
- Oncology 307
- Cancer Research 263
- Immunology 160
- Aging 112
Countries citing papers authored by Norihisa Hanada
This map shows the geographic impact of Norihisa Hanada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norihisa Hanada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norihisa Hanada more than expected).
Fields of papers citing papers by Norihisa Hanada
This network shows the impact of papers produced by Norihisa Hanada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norihisa Hanada. The network helps show where Norihisa Hanada may publish in the future.
Co-authorship network of co-authors of Norihisa Hanada
This figure shows the co-authorship network connecting the top 25 collaborators of Norihisa Hanada. A scholar is included among the top collaborators of Norihisa Hanada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norihisa Hanada. Norihisa Hanada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 3 | |
| 4 | 1 | |
| 5 | 2 | |
| 6 | [Two cases of recurrent GIST successfully treated with imatinib mesylate at 100mg/day]. | 1 |
| 7 | 3 | |
| 8 | 2 | |
| 9 | 2 | |
| 10 | 5 | |
| 11 | 0 | |
| 12 | 1 | |
| 13 | [A case of partial response in liver metastatic lesion from gastric endocrine cell carcinoma treated with TS-1]. | 3 |
| 14 | 3 | |
| 15 | 150 | |
| 16 | IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a breakdown → | 742 |
| 17 | 0 | |
| 18 | 91 | |
| 19 | 23 | |
| 20 | [Successful chemotherapy based on in vitro chemosensitivity testing in a case of recurrent thymic carcinoma]. | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.